Cargando…
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases
Signal transduction and activator of transcription (STAT) proteins are extracellular ligand-responsive transcription factors that mediate cell proliferation, apoptosis, differentiation, development and the immune response. Aberrant signals of STAT induce uncontrolled cell proliferation and apoptosis...
Autores principales: | Hayakawa, F, Sugimoto, K, Harada, Y, Hashimoto, N, Ohi, N, Kurahashi, S, Naoe, T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880446/ https://www.ncbi.nlm.nih.gov/pubmed/24292418 http://dx.doi.org/10.1038/bcj.2013.63 |
Ejemplares similares
-
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
por: Oh, Do-Youn, et al.
Publicado: (2015) -
STAT3 Inhibitor OPB-51602 Is Cytotoxic to Tumor Cells Through Inhibition of Complex I and ROS Induction
por: Brambilla, Lara, et al.
Publicado: (2020) -
A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
por: Tolcher, Anthony, et al.
Publicado: (2018) -
Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
por: Yoo, Changhoon, et al.
Publicado: (2019) -
Tracking mutation and drug-driven alterations of oncokinase
conformations
por: Feichtner, Andreas, et al.
Publicado: (2022)